Akebia Therapeutics (AKBA) Operating Leases (2019 - 2025)
Historic Operating Leases for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $4.9 million.
- Akebia Therapeutics' Operating Leases fell 5173.09% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year decrease of 5173.09%. This contributed to the annual value of $3.5 million for FY2024, which is 6035.54% down from last year.
- Latest data reveals that Akebia Therapeutics reported Operating Leases of $4.9 million as of Q3 2025, which was down 5173.09% from $6.3 million recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Operating Leases registered a high of $37.7 million during Q1 2022, and its lowest value of $3.5 million during Q4 2024.
- Over the past 5 years, Akebia Therapeutics' median Operating Leases value was $16.2 million (recorded in 2023), while the average stood at $20.2 million.
- Per our database at Business Quant, Akebia Therapeutics' Operating Leases surged by 3688.72% in 2021 and then tumbled by 6910.67% in 2023.
- Over the past 5 years, Akebia Therapeutics' Operating Leases (Quarter) stood at $33.7 million in 2021, then fell by 14.07% to $29.0 million in 2022, then tumbled by 69.11% to $8.9 million in 2023, then plummeted by 60.36% to $3.5 million in 2024, then soared by 39.16% to $4.9 million in 2025.
- Its last three reported values are $4.9 million in Q3 2025, $6.3 million for Q2 2025, and $7.6 million during Q1 2025.